Market Overview

Nomura Just Cut Its Price Target On Gilead

Nomura Just Cut Its Price Target On Gilead
Related GILD
Gilead Looking To Buy Incyte? It Makes Sense
Wall Street's M&A Chatter From March 10-12
Marketplace Roundtable: Biotech Hanging In The Balance (Seeking Alpha)

Want an edge on biotech stocks? Try this.

Learn more about investing in the biotech sector with real-time trading picks from experts like the Biotech Trader.

Nomura cut its price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $146 to $141 and maintained a Buy rating following the release of the company’s Q4 earnings results on Tuesday.

Analyst M. Ian Somaiya thought that consensus estimates for 2015 would be lowered due to the “shock of aggressive discounting by Gilead (46 percent vs. our 20 percent estimate) on its HCV drugs.”

On the upside, however, Somaiya noted that the company has secured open access for patients and raised the competitive bar which, along with drug discounting, should “lead to significantly higher patient volume” and allow Gilead to maintain market share with “Harvoni’s best-in-class profile.”

Somaiya called “all investors seeking value” to give attention to the stock and estimated fiscal year 2015 EPS at $10.13 and fiscal year 2016 EPS at $10.86.

Gilead traded down nearly 10 percent during Wednesday's trading.

Image credit: Jeffrey Beall, Wikimedia

Latest Ratings for GILD

Mar 2017UBSDowngradesBuyNeutral
Feb 2017CitigroupDowngradesBuyNeutral
Nov 2016Stifel NicolausInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

The following article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: M. Ian Somaiya NomuraAnalyst Color Price Target Analyst Ratings Best of Benzinga


Related Articles (GILD)

View Comments and Join the Discussion!